Avidity Biosciences Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2020 - 2018
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2020 - 2018
Net Income	-684.63	-322.3	-212.22	-174	-118.01	Upgrade
Depreciation & Amortization	4.15	2.78	2.1	1.39	0.64	Upgrade
Loss (Gain) From Sale of Assets	0.14	-	-	-	-	Upgrade
Loss (Gain) From Sale of Investments	-12.52	-21.45	-11.27	-0.62	0.18	Upgrade
Stock-Based Compensation	97.84	51.36	38.22	27.14	17.06	Upgrade
Other Operating Activities	4.24	3.3	2.98	2.75	0.68	Upgrade
Change in Accounts Payable	3.8	-0.35	4.17	18.32	6.04	Upgrade
Change in Unearned Revenue	-8.62	-10.32	62.99	-5.12	-4.44	Upgrade
Change in Other Net Operating Assets	-54.84	-3.89	-6.03	-6.13	3.04	Upgrade
Operating Cash Flow	-650.44	-300.87	-119.06	-136.27	-94.81	Upgrade
Capital Expenditures	-13.32	-7.07	-4.23	-2.82	-3.74	Upgrade
Investment in Securities	-20.65	-847.14	-125.84	-187.13	-78.78	Upgrade
Other Investing Activities	-4.07	-	-	-	-	Upgrade
Investing Cash Flow	-38.04	-854.2	-130.07	-189.96	-82.52	Upgrade
Issuance of Common Stock	863.4	1,051	93.86	346.17	176.32	Upgrade
Repurchase of Common Stock	-12.41	-	-	-	-	Upgrade
Other Financing Activities	-	141.4	-	-	-	Upgrade
Financing Cash Flow	850.99	1,192	93.86	346.17	176.32	Upgrade
Foreign Exchange Rate Adjustments	0.14	-	-	-	-	Upgrade
Net Cash Flow	162.65	37.29	-155.27	19.95	-1.01	Upgrade
Free Cash Flow	-663.76	-307.94	-123.29	-139.09	-98.55	Upgrade
Free Cash Flow Margin	-3539.11%	-2825.88%	-1289.66%	-1507.92%	-1056.76%	Upgrade
Free Cash Flow Per Share	-4.82	-2.76	-1.69	-2.67	-2.38	Upgrade
Levered Free Cash Flow	-341.02	-197.47	-86.66	-71.82	-48.59	Upgrade
Unlevered Free Cash Flow	-341.02	-197.47	-86.66	-71.82	-48.59	Upgrade
Change in Working Capital	-59.66	-14.56	61.13	7.07	4.64	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.